ProMIS Neurosciences strengthens global IP portfolio

ProMIS Neurosciences announced that the European Patent Office, Japanese Patent Office and IP Australia, the Australian patent office, have recently allowed composition of matter and method of use patent applications related to ProMIS Neurosciences’ lead product candidate, PMN310, for the treatment of Alzheimer’s disease. PMN310 is the Company’s novel monoclonal antibody that is designed to be highly selective for toxic oligomers of amyloid-beta, which are believed to be a major driver of AD. The United States Patent and Trademark Office also recently granted US Patent 11,905,317 directed to immunogenic compositions of matter that are being developed for treating AD. Protection for the immunogenic compositions of matter has also been obtained in Japan, Korea, India and Australia. Further, patent applications were also recently allowed in the U.S. and Japan for two other Abeta targets. The newly allowed patents add to the six patents granted in 2023, four of which relate to PMN310 and bring the total of issued or allowed patents pertaining to the PMN310 portfolio to 10. The recently allowed and granted patents are either co-owned or exclusively licensed from The University of British Columbia as part of a patent portfolio comprising over 25 issued or allowed patents and includes numerous other patent applications.